Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer

Exclusion Criteria

• •Previous chemotherapy, hormone therapy and/or radiotherapy for breast cancer.
• •Bilateral breast cancer. Lobular in situ carcinoma.
• •Previous or current malignancies, except for basal skin carcinoma, cervical in situ carcinoma or superficial bladder carcinoma, adequately treated.
• •History of arrhythmias and/or congestive heart failure or cardiac blocking grade 2-3; history of myocardial infarction in 6 months before recruitment.
• •Inability for treatment and study compliance.
• •Pregnant or lactating women.
• •Active infection.
• •History of hypersensitivity to cremophor or cyclosporine.
• •Pre-existing grade 2 motor or sensorial neurotoxicity (National Cancer Institute Common Toxicity Criteria \[NCI CTC\]).
• •Hormonal receptor status not determined.
• •Any other criteria which, in investigator's opinion, may jeopardize patient's security or compliance.
• •Administration of other investigational product in the 30 days prior to randomisation; current participation in another clinical trial.